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Introduction. Transarterial chemoembolization (TACE) is a good choice for hepatocellular carcinoma (HCC) treatment when
surgery and liver transplantation are not feasible. Few studies reported the value of prognostic factors influencing survival after
chemoembolization. In this study, we evaluated whether preoperative inflammatory factors such as neutrophil to lymphocyte
ratio and platelet to lymphocyte ratio affected our patient survival when affected by hepatocellular carcinoma. Methods. We
retrospectively evaluated a total of 72 patients with hepatocellular carcinoma that underwent TACE. We enrolled patients with
different etiopathogeneses of hepatitis and histologically proven HCC not suitable for surgery. The overall study population was
dichotomized in two groups according to the median NLR value and was analyzed also according to other prognostic factors.
Results. The global median overall survival (OS) was 28 months. The OS in patients with high NLR was statistically significantly
shorter than that in patients with low NLR. The following pretreatment variables were significantly associated with the OS in
univariate analyses: age, Child-Pugh score, BCLC stage, INR, and NLR. Pretreated high NLR was an independently unfavorable
factor for OS. Conclusion. NLR could be considered a good prognostic factor of survival useful to stratify patients that could
benefit from TACE treatment.
1. Background
Hepatocellular carcinoma, a highly insidious and prevalent
tumor, is the sixth most common neoplasia and the third
leading cause of cancer-related death worldwide [1]. Surgery
is the treatment of choice for resectable HCC in an early stage
of disease and in eligible patients with a good liver function.
Unfortunately, the intrahepatic recurrence rate is about
70% within 5 years after surgical resection. Most patients
with HCC are diagnosed in an advanced stage when surgery
and liver transplantation are not feasible; in this scenario,
TACE is considered a good choice of treatment.
As a matter of fact, TACE, as demonstrated in the review
written by Llonej and Bruix [2], showed a survival improve-
ment compared to supportive care in patients affected by
unresectable tumors. TACE can be offered to well-
compensated patients with cirrhosis as a method to reduce
their disease burden and potentially extend their life, as it is
a reasonable and well-tolerated treatment with a minimal
acceptable morbidity.
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Few studies reported the value of prognostic factors
influencing survival after chemoembolization. Recently, there
are increasing evidences that systemic inflammationcorrelates
with cancer patients’ survival and prognosis. Studies have
demonstrated that host inflammatory response to cancer cells
is associated with tumor progression [3–9]. During the past
decade, a variety of inflammatory factors have been identified
as prognostic indicators of cancer -related survival.
Maltoni et al. [10] found that biological factors, such as
leukocytosis, lymphocytopenia, and CRP, reached level B
evidence-based recommendations of prognostic correlation
in advanced cancer patients. In the last years, various
markers of systemic inflammatory response including cyto-
kines, neutrophil to lymphocyte ratio (NLR) and platelet to
lymphocyte ratio (PLR) have been investigated for their
prognostic roles in certain cancer patients [11]. In advanced
gastrointestinal tumors, a high preoperative C-reactive pro-
tein level and high platelet count were frequently observed
and were associated with poor patient prognosis [12]. The
preoperative NLR also reflects patients’ inflammation status,
clinical stage, and patients’ survival in colon cancer, lung
cancer, and gastric cancer. Increased numbers of neutrophils
and/or decreased numbers of lymphocytes may suppress
lymphokine-activated killer cells, thereby increasing the
propensity to metastasis.
Recently, the study of Jin et al. [13] demonstrated that
baseline NLR and d-NLR may serve as convenient, easily
measured prognostic indicators in advanced gastric cancer
patients treated with preoperative chemotherapy and
sequential R0 resection, especially to baseline NLR, which
showed independent prognostic significance on RFS and
OS. Also, the N/L ratio is considered an independent
prognostic factor of survival in patients with gallbladder
carcinoma as shown by Zhang et al. [14].
The NLR has been studied also in HCC patients who
have undergone curative hepatic resection, radiofrequency
ablation, and liver transplantation.
Basedon the results of the recent studyofArai et al. [15], an
elevated preoperative NLR is an independent predictive risk
factor for patients undergoing a two-stage treatment with
reductive surgerypluspercutaneous isolatedhepaticperfusion
for multiple HCC with portal vein tumor thrombus.
In the study of Liao et al. [16], it was indicated that
preoperative NLR, divided by X-tile for the cut point, is a
simple prognostic marker for the patients with single-
nodule HCC after curative surgical resection.
Only few studies have shown that an elevated pre-TACE
NLR is associated with decreased survival.
A recent study done by Megan E. has demonstrated
that periprocedural trends of serum NLR were associated
with oncological outcomes in unresectable HCC undergoing
TACE [17].
He assessed that serum NLR may be helpful to clinicians
in providing prognostic information and monitoring
response to therapy.
Xu et al. [18] demonstrated that preoperative NLR was an
important and independent prognostic factor to predict the
prognosis of 178 patients with intermediate HCC treated
with TACE.
In this study, we evaluated whether preoperative inflam-
matory factors affected our patient survival outcomes who
underwent TACE.
2. Methods
2.1. Patients. We retrospectively evaluated a total of 72
patients with hepatocellular carcinoma (HCC) who under-
went TACE from January 2011 through December 2014 at
the Radiology Department of our institution. Patients’
records/information were anonymized and deidentified prior
to analysis, so that an approval by the Ethic Committee was
not necessary.
All the patients underwent either a CT scan or MRI in
order to evaluate the extent of the disease. A multidisciplin-
ary team decided the treatment to perform.
TACE was recommended for patients not eligible to
undergo curative treatment including surgical resection, liver
transplantation, and percutaneous ablation therapy. The
eligibility criteria to select patients were as follows: absence
of portal vein trunk involvement or extrahepatic metastasis;
Child class A or B; platelet count> 60.000/mm3; and absence
of ongoing spontaneous bacterial peritonitis.
We included, as shown in Figure 1, patients who under-
went at least one TACE procedure and up to three proce-
dures in three consecutive months. We excluded 20
patients because of incomplete data and medical history.
The study population consisted of 49 patients, 39 men
(80%) and 10 women (20%), with a median age of 75 years
(range 49 to 88 years).
We enrolled patients with different etiopathogeneses of
hepatitis: 18 hepatitis C virus, 19 criptogenetic, 10 alcohol
related, and 2 hepatitis B virus. In 18 cases, HCC had a
bilobar dissemination. Our patients had a different number
of lesions: less than 3 lesions in 25 patients, between 3 and
5 lesions in 9 patients, and more than 5 lesions in 15 patients.
Thirty-eight patients had an A5 or A6 Child-Pugh class,
and 11 had a B class. All patients had an intermediate BCLC
stage and underwent TACE even if in Child A class,
72 hcc patients
20 had no complete data
2 perfomed four times the
procedure
1 refused the procedure
52 hcc patients
50 hcc patients
49 patients enrolled
Figure 1: Flow chart of the patients enrolled.
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according to Milan criteria. Overall and NLR subgroup
patients’ characteristics are shown in Table 1.
2.2. TACE Technique. A 5-F introducer sheath was posi-
tioned in the common femoral artery. Selective catheteriza-
tion of the hepatic artery was performed using 4- to 5-F
catheters with different shapes and an 0.035^ hydrophilic
guide wire (Glidewire, Terumo Europe, Leuven, Belgium);
then a microcatheter (Progreate, Terumo Europe, Leuven,
Belgium) was inserted coaxially. Superselective catheteriza-
tion of the main feeders was performed whenever possi-
ble. The DEB-TACE protocol used DC beads (100–300
and 300–500μm; Biocompatibles, Surrey, UK) loaded with
50–75mg of epirubicin hydrochloride. The loaded beads
were mixed with iodinate contrast medium and saline to
a ratio of 8 : 2 to optimize visualization during the infu-
sion procedure. The embolization endpoint was deter-
mined by occlusion of HCC-feeding arteries; when not
achieved, Spongostan pledgets were injected to obtain
complete stasis.
2.3. Follow-Up. A CT or RMN was performed at 1 month
from the procedure to assess radiographic response to TACE
and 6 months thereafter.
The overall survival time (OS) was calculated from the
date of the first TACE procedure to the date of death pro-
vided by the regional registry office, or at the conclusion
of the study, end of June 2015. The progression free sur-
vival (PFS) was determined as the time lapse between
the procedure and the progression of the disease defined
according to mRECIST criteria [19]. Follow-up imaging
was available at our institution only for 39 patients who
were selected to evaluate the PFS; median PFS of all
patients was 12 months.
2.4. Data Collection and Blood Samples.Demographic details,
drug used during TACE, and survival data were prospectively
collected using clinical records into a database. One venous
blood sample was taken the day before the procedure and
collected in an ethylenediaminetetraacetic acid-containing
tube according to other studies present in the literature.
The numbers of WBCs and platelets were determined with
a hemocytometer. Absolute counts of particular cells were
calculated by multiplying the percentage of particular cells
by the number of WBCs. Patients were dichotomized on
the basis of a median cutoff value, classifying high and low
groups, and survival curves were analyzed for NLR and
PLR. Preoperative NLR and PLR were calculated as the
neutrophil/platelet count divided by the lymphocyte count.
Table 1: Overall, high and low NLR subgroups patients’ characteristics and statistical differences between the two subgroups.
Mean (min-max) or frequencies
n = 49
Overall Low NLR High NLR p value
Sex (male/female) 39/10 16/9 23/1 0.0106∗
Age (years) 75 (49–88)┼ 75 (49–88)┼ 74 (51–86)┼ 0.477∗∗
Etiology (HCV/Cripto/Alcol/others) 18/19/10/2 11/9/3/2 7/10/7/0 0.2102∗∗
Child-Pugh class (5/6/7/8/9) 17/21/7/3/1 8/10/5/1/1 9/11/2/2/0 0.6081∗∗
Neutrophil (/mm3) 3485 (811–9130)┼ 2389 (811–6019)┼ 4533 (1920–9130)┼ 0.002∗∗∗
Lymphocyte (/mm3) 1321 (360–2970)┼ 1553 (759–2970)┼ 1110 (360–1977)┼ 0.0107∗∗∗
Neutrophil/lymphocyte
3.25 (0.61–19.02)┼
Median 2.03
1.5 (0.61–2.03)┼ 5.06 (2.19–19.02)┼ 0.0004∗∗∗
Platelet (/mm3) 115.857 (51.000–243.000)┼ 111.041 (51.000–243.000)┼ 117.000 (53.000–188.000)┼ 0.6607∗∗∗
Platelet/lymphocyte 99 (33–391)┼ 75.43 (33.69–142.83)┼ 124.40 (52.50–391.78)┼ 0.0048∗∗∗
BCLC stage (B/C) 34/15 17/8 17/7 0.9244∗∗
Tumor size (<5/>5 cm) 23/26 13/11 10/15 0.4796∗∗
Number of tumors (<3/3–5/>5) 25/9/15 15/4/6 10/5/9 0.4293∗∗
Extrahepatic spread (absent/present) 49/0 25/0 24/0 1.0∗∗
Bilobar spread (absent/present) 18/31 12/13 6/18 0.1697∗∗
Ascites (absent/present) 37/12 20/5 17/7 0.6791∗∗
Albumin (g/dL) 3.70 (2.51–4.80)┼ 3.55 (2.51–4.46)┼ 3.83 (2.77–4.80)┼ 0.7460∗∗∗
Bilirubin (mg/dL) 1.04 (0.08–3.07)┼ 0.96 (0.08–2.42)┼ 1.11 (0.32–3.07)┼ 0.6570∗∗∗
INR 1.18 (0.92–1.68)┼ 1.20 (0.92–1.68)┼ 1.16 (1.00–1.40)┼ 0.1409∗∗∗
Creatinine (mg/dL) 0.90 (0.45–2.28)┼ 0.84 (0.45–1.80)┼ 0.95 (0.57–2.28)┼ 0.2198∗∗∗
GFR (mL/min) 96.56 (29.00–197.00)┼ 100.09 (29.00–197.00)┼ 93.63 (30.00–146.00)┼ 0.4283∗∗∗
∗Fisher’s exact test; ∗∗χ2-test; ∗∗∗Student’s t-test; ┼min-max; BCLC = Barcelona Clinic Liver Cancer; Cripto = criptogenetic; GFR = glomerular filtration rate;
HCV= hepatitis C virus; INR = International Normalized Ratio; NLR = neutrophil to lymphocyte ratio; PLR = platelet to lymphocyte ratio.
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The patients were dichotomized at the median value of NLR,
PLR, albumin, bilirubin, Child-Pugh class, and the presence
or absence of ascites. Median value was recalculated when
analyzing subgroups.
Data are collected on the approval of our Institutional
Ethics Committee.
2.5. Statistical Analysis. Patients’ descriptive analysis was
generated, and their differences were investigated using
Student t-test for quantitative data; for qualitative data, we
used Fisher’s exact test or chi-square test.
To compare OS and PFS between groups, the cumulative
survival proportions were calculated using the product limit
Table 2: Pretreatment factors affecting progression free survival.
n mPFS Univariate p∗ Hazard ratio (95% CI) Multivariate p∗∗
Sex
Male 39 10
0.4581
Female 10 12
Age (years)
>76 25 15
0.9328<76 24 6
Etiology
HCV 18 10
0.1911
Cripto 19 6
Alcol 10 17
Others 2 20
Child-Pugh class
5 17 12
0.5016
6 21 6
7 7 15
8 3 —
9 1 —
NLR
>2.03 25 8
0.4403<2.03 24 12
PLR
>87.99 25 7
0.3800<87.99 24 14
BCLC stage
B 34 10
0.1457
C 15 14
Tumor size (cm)
>5 26 12
0.9600<5 23 11
Number of tumors
<3 25 12
0.73203–5 9 5
>5 15 10
Extrahepatic spread
Absent 49 12
—
Present 0 —
Bilobar spread
Absent 18 10
0.8673
Present 31 12
Ascites
Absent 37 14
0.1823
Present 12 10
Albumin
>3.7 25 8
0.2176<3.7 24 15
Bilirubin
>0.84 25 8
0.0841<0.84 24 16
INR
>1.18 25 15
0.5610<1.18 24 10
Creatinine
>0.78 25 5
0.0350 3.4639 (0.7593–15.8025) 0.1104<0.78 24 15
GFR
>94.5 25 17
0.0429 0.6264 (0.1437–2.7311) 0.5356<94.5 24 5
∗Log-rank test; ∗∗Cox’s proportional hazards regression model.
BCLC = Barcelona Clinic Liver Cancer; Cripto = criptogenetic; GFR = glomerular filtration rate; HCV= hepatitis C virus; INR = International Normalized
Ratio; mOS =median overall survival; mPFS =median progression free survival; NLR = neutrophil to lymphocyte ratio; PLR = platelet to lymphocyte ratio.
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method of Kaplan-Meier, and differences were evaluated
using the log-rank test. Only variables that achieved
statistical significance in the univariate analysis were sub-
sequently evaluated in the multivariate analysis using
Cox’s proportional hazard regression model. A p value of
less than 0.05 was considered statistically significant. All
statistical analyses were performed using the MedCalc Statis-
tical Software version 14.8.1 (MedCalc Software bvba,
Ostend, Belgium).
3. Results
The overall study population was dichotomized in two
groups according to the median NLR value of 2.03; a
high NLR group of 25 patients and a low NLR one of
24 patients.
Group demographic characteristics are summarized in
Table 1.
Patients with high NLR had no significant difference
in demographic characteristics according to the BCLC
stage, age, Child-Pugh stage, etiology, number of lesions,
and tumor size. Bilobar spread represented 75% of the
high NLR group and 50% of the low NLR group. Lym-
phocyte count was significantly lower in the high NLR
group while neutrophil count was higher than in the
low NLR.
The PFS in patients with high NLR was not signifi-
cantly worse than that in the low NLR group. Only
creatine (p = 0 0350) and GFR (p = 0 0429) were associated
Overall survival in high and low NLR groups
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Figure 2: Kaplan-Meier curves showing a significant statistical
difference in the OS between the high and low NLR groups
(p = 0 0429).
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Figure 3: Kaplan-Meier curves showing a significant statistical
difference in OS between Child-Pugh groups (p = 0 0365).
Progression free survival in high and low NLR groups
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Figure 4: Kaplan-Meier curves showing a nonsignificant statistical
difference in PFS between the high and low NLR groups (p > 0 05).
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with the PFS in univariate analyses. No pretreatment
factor correlated with PFS in multivariate analyses. PFS
analyses are resumed in Table 2.
The median OS of all patients was 28 months. The OS in
patients with high NLR was shorter than that in patients with
low NLR (p = 0 0429) (Figure 2). The median OS in patients
with high NLR was 18 months, and it was significantly worse
than that in patientswith lowNLR (46months). The following
5 of the 17 pretreatment variableswere significantly associated
with the OS in univariate analyses: age (p = 0 0325), Child-
Pugh score (p = 0 0365) (Figure 3), BCLC stage (p < 0 0199),
INR (p < 0 0218), and NLR. Pretreatment of high NLR was
Table 3: Pretreatment factors affecting overall survival.
n mOS Univariate p Hazard ratio (95% CI) Multivariate p
Sex
Male 39 46
0.1285
Female 10 23
Age (years)
>76 25 49
0.0325 0.4838 (0.1267–1.8480) 0.2908<76 24 23
Etiology
HCV 18 24
0.9782
Cripto 19 46
Alcol 10 —
Others 2 28
Child-Pugh class
5 17 48
0.0365 0.9823 (0.1690–5.7078) 0.9842
6 21 33
7 7 17
8 3 14
9 1 23
NLR
>2.03 25 18
0.0429 11.5283 (2.3361–56.8918) 0.0028<2.03 24 33
PLR
>87.99 25 24
0.9737<87.99 24 33
BCLC stage
B 34 48
0.0199 1.8542 (0.4128–8.3281) 0.4229
C 15 23
Tumor size (cm)
>5 26 24
0.6515<5 23 33
Number of tumors
<3 25 24
0.25653–5 9 17
>5 15 46
Extrahepatic spread
Absent 49 28
—
Present 0 —
Bilobar spread
Absent 18 46
0.6596
Present 31 24
Ascites
Absent 37 48
0.0964
Present 12 23
Albumin
>3.7 25 —
0.1210<3.7 24 22
Bilirubin
>0.84 25 23
0.2664<0.84 24 33
INR
>1.18 25 22
0.0218 16.9893 (1.6017–180.2098) 0.0193<1.18 24 —
Creatinine
>0.78 25 24
0.7856<0.78 24 24
GFR
>94.5 25 21
0.7606<94.5 24 24
BCLC = Barcelona Clinic Liver Cancer; Cripto = criptogenetic; GFR = glomerular filtration rate; HCV= hepatitis C virus; INR = International Normalized
Ratio; mOS =median overall survival; NLR = neutrophil to lymphocyte ratio; PLR = platelet to lymphocyte ratio.
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an independent unfavorable factor for OS (HR=11.5283;
p = 0 0028) as well as INR (HR=16.9893; p = 0 0193). PLR
did not correlate with the PFR nor the OS (Figure 4). OS
analyses are resumed in Table 3.
We dichotomized the two subgroups Child-Pugh class A
and B using the NLR median value of 2.03; the high NLR
group demonstrated to have a significant worse survival in
both Child-Pugh class A (p = 0 0135) and B (p = 0 0437)
(Figures 5(a) and 5(b)).
4. Discussion
The majority of patients affected by HCC have unresectable
disease at presentation, and transarterial chemoembolization
(TACE) has been widely used in these cases. In this study, we
showed that the simple assessment of inflammatory markers
before TACE is highly predictive of the outcome indepen-
dently from the cirrhosis’ cause. NLR and PLR are associated
with overall survival in patients with unresectable HCC ini-
tially treated with TACE. Specifically, patients with unresect-
able HCC have worse outcomes when NLR or NPR is
elevated before TACE. In fact, patients with NLR superior
to 2.03 have a median survival of 14 months, and patients
with PLR less than 2.03 have a median survival of 20 months.
Since Virchow’s study [20], inflammation has been found
to play an important role in the pathogenesis and progression
of malignant tumors, including HCC [21–23]. Inflamma-
tion promotes tumor angiogenesis, invasion, and tumoral
progression due to an altered regulation of T lymphocytes
and chemokines. In addition, patients with a lymphocyto-
penia may have a higher risk of tumor recurrence and a
worse prognosis [24]. In HCC patients, increase has been
reported to be associated with a lower recurrence rate
and better prognosis [25].
On the other hand, neutrophil stimulation caused an
expression of various cytokines, such as interleukin 8
(IL-8), which is the core of the inflammatory and immune
responses, and it results in tumor progression and metas-
tasis [26].
Neutrophils promote tumor growth and metastasis by
secreting vascular endothelial growth factor, angiopoietin-1,
and matrix metalloproteinase-9. This angiogenic activity
resulting from neutrophilia could increase the metastatic
power of tumor.
A recent meta-analysis written by Xiao et al. [27]
provided a strong evidence that the elevated NLR is prognos-
tically significant in patients with HCC treated by either
curative or palliative methods. To date, only few studies cor-
related inflammatory markers to prognosis of unresectable
HCC patients addressed to TACE.
Various studies aimed at developing a simple validated
prognostic score based on different predictive factors (scor-
ing system, number and size of hepatic lesions, AFP value,
and cirrhosis pathogenesis) of survival and TACE response
in patients with HCC treated with TACE [1]. In his study,
Wenzhe et al. demonstrated that high NLR and PLR were
both associated with poor prognosis and metastasis in recur-
rent HCC patients treated with TACE, but high PLR was a
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Figure 5: Kaplan-Meier curves showing a significant statistical difference between the high and low NLR patients in the Child-Pugh A (a)
and B (b) class subgroups.
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better predictor of a 1-year OS. He showed other prognostic
variables as independent unfavorable factors: vascular inva-
sion and multiple tumors [28].
In our study, NLR demonstrated to correlate with sur-
vival even in patients with the risk already assessed according
to Child-Pugh. We hypothesize that NLR and PLR may be
useful in predicting survival-stratifying patients at high
recurrence risk after TACE. In this way, it allows to make a
stricter follow-up in these patients. In particular, for patients
with abnormal elevation of NLR and/or PLR before TACE, it
may be reasonable to add systemic or biologic therapies to
TACE hoping to achieve better outcomes.
Compared to other prognostic markers, NLR and PLR
seem to be a convenient predictor for HCC patients. It is
low cost, reliable, easily obtainable, and repeatable. The
limitations of the current study arise from factors that could
affect the NLR and PLR of patients with unresectable HCC
before TACE. Viral hepatitis could affect the hymmunestatus
compared to those with HCC who are not infected with hep-
atitis virus. Level of blood neutrophils and platelets could be
reduced by cirrhosis-associated hypersplenia.
Other limitations are related to the retrospective design
of the study and the sample size of studied patients. How-
ever, the utility of these inflammatory parameter markers
should be further validated and compared to treatment-
naive patients.
Further prospective studies are necessary to confirm and
expand our preoperative prognostic score model for patients
with unresectable HCC. A definitive cutoff value of NLR,
based on future large-sample study, is recommended.
5. Conclusion
In view of these findings, perhaps, HCC patients with high
NLR may benefit from anti-inflammatory treatment. We
hope that future research could test this hypothesis.
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